Annual report pursuant to Section 13 and 15(d)

Geographic information

v3.22.4
Geographic information
12 Months Ended
Dec. 31, 2022
Geographic information  
Geographic information

Note 14 — Geographic information

Operations by geographic area

Revenue represents recognized income from the Astellas Collaboration Agreement, the GNE Collaboration and License Agreement and the GSK Collaboration and License Agreement. All revenue was derived in the United Kingdom.

Long-lived assets (excluding intangibles, deferred tax and financial instruments) were located as follows (in thousands):

December 31, 

December 31, 

    

2022

    

2021

U.K.

$

42,387

$

29,701

U.S.

 

29,148

 

21,668

Total long-lived assets

$

71,535

$

51,369

Major customers:

During the year ended December 31, 2022, 21%, 50% and 29% of the Company’s revenues were generated from Astellas, Genentech and GSK, respectively.